Dementia continues to be one of the world’s most pressing public health issues. It’s estimated that more than 55 million people are affected by dementia globally, costing over $1 trillion each year. While there is currently no cure for dementia, a recent Cambridge-led study has uncovered promising links between commonly used medications and a lower dementia risk. This discovery could offer relief and even accelerate the search for effective, accessible preventive strategies to dementia.
Mining Massive Health Data for Clues
Researchers from the University of Cambridge and the University of Exeter conducted a systematic review that analyzed health records from 130 million people, including over one million diagnosed dementia cases. Their goal was to identify whether any widely prescribed drugs, that are already licensed and with certified safety profiles, might be associated with a lower dementia risk.
The study reviewed 14 large-scale studies, using a data-driven approach to explore the relationship between prescription medications and dementia treatment outcomes. The findings revealed that antibiotics, antivirals, vaccines, and anti-inflammatory drugs were all linked to a reduced risk of dementia. Notably, vaccines for hepatitis A, typhoid, and diphtheria were also associated with a lower dementia risk.
Read More: Boosting Magnesium Levels Could Slow Brain Aging and Lower Dementia Risk, Research Shows
Combating Infection and Inflammation
The protective effect of these medications appears to stem from their ability to reduce inflammation, control infections, and support overall brain health. Infections, whether viral or bacterial, can trigger an exaggerated immune response, causing damage to brain cells and accelerating memory decline, increasing the risk of dementia. Antibiotics and antivirals help combat these infections, potentially slowing down harmful immune responses. Vaccines, on the other hand, prevent infections from initially happening, strengthen the immune system against future infections, and reduce the risk of prolonged immune activation and its damaging effects on the brain. This has led researchers to investigate a potential link between viral and bacterial infections and dementia.
The Role of Anti-Inflammatory Drugs
Researchers noted that non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen could protect against dementia. A large study published in the Journal of the American Geriatrics Society found that long-term NSAID use was associated with a 12% reduced risk of developing dementia. Prolonged use of these medications, rather than intensive use, is linked to a sustained reduction of chronic inflammation, suggesting this approach may hold the key to lowering dementia risk.
While inflammation is the body’s natural defense against injury and infection, chronic inflammation can damage healthy brain tissue. This subsequently leads to a disruption in communication between brain cells, ultimately leading to memory loss. By blocking the production of inflammatory molecules, NSAIDs may help protect brain cells from this long-term damage.
Infections and Dementia
Emerging evidence supports the theory that infections and the body’s immune response play a central role in dementia development. A large observational study funded by the National Institute on Aging revealed that people hospitalized with infections faced a 70% greater likelihood of developing dementia years later compared to those who avoided hospitalization for infections. Blood, circulatory, urinary, and hospital-acquired infections particularly increased dementia risk.
A Surprising Ally
Vaccines, primarily used to prevent infectious diseases, may also contribute to lowering dementia risk. The Cambridge-led study found that vaccines for hepatitis A, typhoid, and diphtheria were linked to reduced dementia rates. Other research has shown an association between the BCG vaccine (for tuberculosis) and a decreased risk of Alzheimer’s disease.
Read More: Do Statins Help Prevent Dementia – Or Raise the Risk?
Mixed Results for Other Medications
The study also examined other classes of prescription drugs. Blood-pressure medications, antidepressants, and diabetes drugs were included in the analysis. However, the results were inconsistent across these drug categories. Some blood-pressure medications may lower dementia risk. ACE inhibitors and angiotensin II receptor blockers (ARBs) are examples of such medications. They potentially improve blood flow and reduce inflammation.
Other medications, like beta-blockers, do not appear to offer the same benefits in treating neurodegenerative diseases. Diabetes drugs also showed mixed results. Researchers are exploring whether GLP-1 receptor agonists, like semaglutide, can reduce dementia risk, particularly in people with type 2 diabetes. However, scientists still need more research to determine if these benefits extend to individuals without a diagnosis of diabetes.
The Immune System and Brain Health
Recent genetic studies have revealed that many genes linked to increased dementia risk are active in the brain’s immune cells. Specialized immune cells in the brain, called microglia, serve as the first line of defense, clearing harmful substances and maintaining brain health. However, chronic activation of these cells, as seen in Alzheimer’s disease, can contribute to neurodegeneration. Inflammation elsewhere in the body, triggered by conditions like diabetes, obesity, and cardiovascular disease, can also dither the brain’s ability to safeguard itself from damage and increase dementia risk.
Implications and Next Steps
The discovery that common, widely available medications may help lower dementia risk offers hope for faster, more cost-effective clinical trials. These findings suggest the potential for innovative and preventative strategies moving forward. The discovery that common medications may lower dementia risk offers hope for faster, more cost-effective clinical trials and preventive strategies. Because these drugs already have approval and established safety profiles, researchers can potentially bypass many foundational hurdles. Repurposing them to prevent dementia becomes a more streamlined process.
The Cambridge-led study didn’t determine how long participants used the medications or how often doctors prescribed them. Therefore, future research must explore these factors. Researchers will need to conduct randomized controlled trials to confirm whether these drugs can effectively prevent dementia through repurposing.
A New Direction in Dementia Prevention
By finding new uses for existing drugs, scientists may be able to deliver treatments to patients more quickly and affordably, offering renewed hope in the fight against dementia. As our understanding of the links between infection, inflammation, and brain health deepens, the prospect of lowering dementia risk through common medications becomes increasingly plausible. Now, continued research and robust clinical trials are vital to translate these promising findings into tangible prevention and treatment strategies and ultimately reshape the outlook for millions facing this devastating disease worldwide.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
Read More: 6 Vague Dementia Symptoms You May Not Notice At First
